Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 10/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 8/20 | 1.00 |
| ▸ | HNF4A | P41235 | 2/20 | 1.00 |
| ▸ | DHFR | P00374 | 1/20 | 1.00 |
| ▸ | GSTA1 | P08263 | 1/20 | 0.70 |
| ▸ | LCK | P06239 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23143193 | 1.00 | ACMSD (1.00) | ACMSDMCL1HNF4ADHFRGSTA1 | |
| SCHEMBL330602 | 1.00 | ACMSD (1.00) | ACMSDMCL1HNF4ADHFRGSTA1 | |
| SCHEMBL9273036 | 1.00 | ACMSD (1.00) | ACMSDMCL1HNF4ADHFRGSTA1 | |
| SCHEMBL9652822 | 0.98 | ACMSD (0.96) | ACMSDMCL1HNF4ADHFRGSTA1 | |
| SCHEMBL18224311 | 0.94 | ACMSD (0.88) | ACMSDMCL1HNF4ADHFRGSTA1 | |
| SCHEMBL29374831 | 0.94 | ACMSD (0.88) | ACMSDMCL1HNF4ADHFRGSTA1 | |
| SCHEMBL29904854 | 0.91 | ACMSD (0.83) | ACMSDMCL1HNF4ADHFRLCK | |
| SCHEMBL2771723 | 0.91 | ACMSD (0.83) | ACMSDMCL1HNF4ADHFRLCK | |
| SCHEMBL22206257 | 0.89 | ACMSD (0.80) | ACMSDMCL1HNF4ADHFRLCK | |
| Methane SCHEMBL28165586 | 0.89 | ACMSD (0.80) | ACMSDMCL1HNF4ADHFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220362265-A1 | THERAPY | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2022-11-17 | — | — | US | claimed |
| US-12629382-B2 | Therapy | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2026-05-19 | — | — | US | disclosed |
| US-20220362265-A1 | THERAPY | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2022-11-17 | — | — | US | disclosed |
| EP-4021504-A1 | THERAPY | Vestlandets Innovasjonsselskap AS (NO) | 2022-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629382-B2 | Therapy | NR3C1, MGMT, GRM3 | ACMSD 4839/4885MCL1 127/4885HNF4A 1192/4885 |
| US-20220362265-A1 | THERAPY | GRM3, GLRX3, CBR3 | ACMSD 4783/4885MCL1 1383/4885HNF4A 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.